China Biologic Products Holdings, Inc. engages in the research, development, manufacture, and sale of human plasma-based biopharmaceutical products to hospitals and inoculation centers in the People's Republic of China. It offers human albumin for treating shock caused by blood loss trauma or burn; raised intracranial pressure caused by hydrocephalus or trauma; oedema or ascites caused by hepatocirrhosis and nephropathy; and neonatal hyperbilirubinemia, as well as for the prevention and treatment of low-density-lipoproteinemia. The company also provides human immunoglobulin for intravenous injection products for original and secondary immunoglobulin deficiency, and auto-immune deficiency diseases; human hepatitis B immunoglobulin for the prevention of measles and contagious hepatitis; human rabies immunoglobulin primarily for passive immunity from bites or claws by rabies or other infected animals; and human tetanus immunoglobulin for the prevention and therapy of tetanus. In addition, it offers placenta polypeptide for the treatment of cell immunity deficiency diseases, viral infection, and leucopenia, as well as assists in postoperative healing; factor VIII for treating coagulopathies; human fibrinogen; and human prothrombin complex concentrate for treating congenital and acquired clotting factor II, VII, IX, X deficiency, as well as excessive anticoagulant, vitamin K deficiency, etc. Further, the company is developing immune globulin intravenous; human antithrombin III; Caprylate/Chromatography Purified and 20 nm virus filtration; human coagulation factor IX; human cytomegalovirus immunoglobulin; and human fibrin sealant products. The company sells its products directly, as well as through distributors. The company was formerly known as China Biologic Products, Inc. and changed its name to China Biologic Products Holdings, Inc. in July 2017. China Biologic Products Holdings, Inc. is headquartered in Beijing, the People's Republic of China.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:CBPO
CUSIPN/A
Phone86-10-6598-3111
Debt
Debt-to-Equity RatioN/A
Current Ratio6.25
Quick Ratio4.27
Price-To-Earnings
Trailing P/E Ratio14.24
Forward P/E Ratio19.00
P/E Growth1.47
Sales & Book Value
Annual Sales$370.41 million
Price / Sales6.31
Cash Flow$4.6199 per share
Price / Cash15.26
Book Value$20.05 per share
Price / Book3.52
Profitability
EPS (Most Recent Fiscal Year)$4.95
Net Income$67.94 million
Net Margins15.89%
Return on Equity14.00%
Return on Assets12.16%
Miscellaneous
Employees1,912
Outstanding Shares33,130,000
Market Cap$2.35 billion
China Biologic Products (NASDAQ:CBPO) Frequently Asked Questions
What is China Biologic Products' stock symbol?
China Biologic Products trades on the NASDAQ under the ticker symbol "CBPO."
How were China Biologic Products' earnings last quarter?
China Biologic Products Holdings Inc (NASDAQ:CBPO) announced its quarterly earnings data on Friday, August, 3rd. The biopharmaceutical company reported $1.17 earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of $1.26 by $0.09. The biopharmaceutical company earned $120.40 million during the quarter, compared to the consensus estimate of $116.21 million. China Biologic Products had a net margin of 15.89% and a return on equity of 14.00%. The firm's quarterly revenue was up 34.8% compared to the same quarter last year. During the same period in the prior year, the firm earned $1.35 earnings per share. View China Biologic Products' Earnings History.
When is China Biologic Products' next earnings date?
What price target have analysts set for CBPO?
3 brokerages have issued 1-year price targets for China Biologic Products' shares. Their predictions range from $97.00 to $105.00. On average, they anticipate China Biologic Products' stock price to reach $101.00 in the next year. This suggests a possible upside of 43.3% from the stock's current price. View Analyst Price Targets for China Biologic Products.
What is the consensus analysts' recommendation for China Biologic Products?
3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for China Biologic Products in the last year. There are currently 2 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for China Biologic Products.
Who are some of China Biologic Products' key competitors?
Some companies that are related to China Biologic Products include Qiagen (QGEN), AveXis (AVXS), BIO-TECHNE (TECH), bluebird bio (BLUE), Ablynx (ABLYF), Aerie Pharmaceuticals (AERI), argenx (ARGX), Repligen (RGEN), Halozyme Therapeutics (HALO), Acceleron Pharma (XLRN), Regenxbio (RGNX), Spark Therapeutics (ONCE), Crispr Therapeutics (CRSP), Atara Biotherapeutics (ATRA) and Denali Therapeutics (DNLI).
Who are China Biologic Products' key executives?
China Biologic Products' management team includes the folowing people:
- Mr. Zhijun Tong, Pres & Director (Age 58)
- Mr. Ming Yang, Chief Financial Officer (Age 46)
- Mr. Ming Yin, Sr. VP (Age 40)
- Ms. Zhijing Liu, Corp. VP (Age 64)
- Mr. Gang Yang, Corp. VP & GM of Guizhou Taibang (Age 53)
Who are China Biologic Products' major shareholders?
China Biologic Products' stock is owned by a number of of institutional and retail investors. Top institutional investors include Fox Run Management L.L.C. (0.01%). Company insiders that own China Biologic Products stock include David Gao, Sean Shao and Zhijing Cbpo Liu. View Institutional Ownership Trends for China Biologic Products.
Which major investors are buying China Biologic Products stock?
How do I buy shares of China Biologic Products?
Shares of CBPO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is China Biologic Products' stock price today?
One share of CBPO stock can currently be purchased for approximately $70.50.
How big of a company is China Biologic Products?
China Biologic Products has a market capitalization of $2.35 billion and generates $370.41 million in revenue each year. The biopharmaceutical company earns $67.94 million in net income (profit) each year or $4.95 on an earnings per share basis. China Biologic Products employs 1,912 workers across the globe.
What is China Biologic Products' official website?
How can I contact China Biologic Products?
China Biologic Products' mailing address is 18TH FL JIALONG INTERNATIONALBUILDING 19 CHAOYANG PARK ROAD CHAOYANG DISTRICT, BEIJING F4, 100125. The biopharmaceutical company can be reached via phone at 86-10-6598-3111 or via email at [email protected]
MarketBeat Community Rating for China Biologic Products (NASDAQ CBPO)
MarketBeat's community ratings are surveys of what our community members think about China Biologic Products and other stocks. Vote "Outperform" if you believe CBPO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CBPO will underperform the S&P 500 over the long term. You may vote once every thirty days.
